Results 121 to 130 of about 16,542 (247)

Differential Roles for IL‐4Rα and IL‐13Rα1 in Immune Cell Infiltration and Epithelial Remodeling in Experimental Eosinophilic Gastritis

open access: yesAllergy, EarlyView.
This study described the development of an experimental model for eosinophilic gastritis (EoG). Experimental EoG recapitulates histopathological features of human disease. including foveolar elongation, fibrosis, eosinophilia, mastocytosis and shared transcriptional programs.
Anish Dsilva   +7 more
wiley   +1 more source

Friend or Foe? Eosinophilic Granulomatosis with Polyangiitis (EGPA) Onset After Dupilumab: Report of Two Cases and a Narrative Review of the Literature

open access: yesRheumato
Background/Objectives: Dupilumab is a fully human IgG4 monoclonal antibody targeting the interleukin-4 receptor α subunit, inhibiting interleukin-4 and interleukin-13 signalling, and suppressing type 2 inflammation.
Alessia Gatti   +6 more
doaj   +1 more source

Dupilumab‐Induced Erythrodermic Psoriasiform Dermatitis in Chronic Actinic Dermatitis: Case Report and Innovative Treatment Approach

open access: yesClinical Case Reports
The off‐label use of dupilumab has proven to be an effective treatment option for severe chronic actinic dermatitis (CAD). We present the first case of CAD presenting with dupilumab‐induced erythrodermic psoriasiform dermatitis.
Joe Khodeir, Maya Habre
doaj   +1 more source

Serum‐Proteomic Profiling Reveals Distinct Atopic Dermatitis Severity‐Linked Signatures

open access: yesAllergy, EarlyView.
This study aimed to identify a set of serum biomarkers that robustly distinguish prespecified severe from mild atopic dermatitis groups. Serum proteomic profiling distinguishes severe from mild atopic dermatitis, revealing an epithelial enriched severity footprint linked to LDH‐associated tissue injury and Th2/Th22 inflammation.
Jag S. Lally   +6 more
wiley   +1 more source

Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis

open access: yesJournal of Dermatological Treatment
Purpose Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.Material and methods This case report details a 52-year-old female patient with atopic
C. Grote   +3 more
doaj   +1 more source

Rademikibart for Asthma With Type 2 Biomarkers: Exploratory Subgroup Analyses From a Phase 2b Randomized Clinical Trial

open access: yesAllergy, EarlyView.
This study reports exploratory and predominantly post hoc subgroup analyses, according to baseline eosinophil count and FeNO levels. In adults with moderate‐to‐severe uncontrolled asthma, rademikibart produced rapid and sustained improvements in lung function and asthma control.
Michael E. Wechsler   +3 more
wiley   +1 more source

A pediatric case of dupilumab-induced pustular psoriasis

open access: yes
Aim: Dupilumab is a novel treatment agent for moderate to severe atopic dermatitis (AD) with few adverse effects. Drug-induced psoriasiform lesions are rare.Methods: We report a 4-year-old boy with AD who developed pustular psoriasis during treatment ...
Yunqing Ren, Nan Dang, Huiwen Zheng
core   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

open access: yesAllergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz   +22 more
wiley   +1 more source

Spatial Transcriptomics Identifies Characteristic Immunological Niches in Atopic Dermatitis

open access: yesAllergy, EarlyView.
Spatially organized immune niches containing mature migratory dendritic cells (mmDCs) and CD4+ T cells in atopic dermatitis lesions support localized T cell activation and may contribute to disease persistence. Spatial transcriptomics identifies conserved immune niches in atopic dermatitis lesions, characterized by close co‐localization of CD4+ T cells
Lina Gross   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy